Page 136 - Remedial Andrology
P. 136

more reliable in different routine genetic laboratories. The EAA guidelines provide a set of primers capable of
                        detecting > 95% of clinically relevant deletions [1541].

                        10.3.5.3.1.2   Genetic counselling for AZF deletions
                        After conception, any Y-deletions are transmitted to the male offspring, and genetic counselling is therefore
                        mandatory. In most cases, father and son will have the same microdeletion [1541], but occasionally the son
                        may have a more extensive deletion [1542]. The extent of spermatogenic failure (still in the range of azoo-/
                        oligo-zoospermia) cannot be predicted entirely in the son, due to the different genetic background and the
                        presence or absence of environmental factors with potential toxicity on reproductive function. A significant
                        proportion of spermatozoa from men with complete AZFc deletion are nullisomic for sex chromosomes [1543,
                        1544], indicating a potential risk for any offspring to develop 45,X0 Turner’s syndrome and other phenotypic
                        anomalies associated with sex chromosome mosaicism, including ambiguous genitalia  [1545]. Despite this
                        theoretical risk, babies born from fathers affected by Yq microdeletions are phenotypically normal [1540, 1541].
                        This could be due to the reduced implantation rate and a likely higher risk of spontaneous abortion of embryos
                        bearing a 45,X0 karyotype.

                        10.3.5.3.1.3   Y-chromosome: ‘gr/gr’ deletion
                        A new type of Yq deletion, known as the gr/gr deletion, has been described in the AZFc region [1546]. This
                        deletion removes half of the gene content of the AZFc region, affecting the dosage of multicopy genes
                        mapping inside this region. This type of deletion confers a 2.5-8 fold increased risk for oligozoospermia [1541,
                        1547-1549]. The frequency of gr/gr deletion in oligozoospermic patients is ~5% [1550].

                        According to four meta-analyses, gr/gr deletion is a significant risk factor for impaired sperm production [1548-
                        1550]. It is worth noting that both the frequency of gr/gr deletion and its phenotypic expression vary among
                        different ethnic groups, depending on the Y-chromosome background. For example, in some Y haplo-groups,
                        the deletion is fixed and appears to have no negative effect on spermatogenesis. Consequently, the routine
                        screening for gr/gr deletion is still a debated issue, especially in those laboratories serving diverse ethnic and
                        geographic populations. A large multi-centre study has shown that gr/gr deletion is a potential risk factor for
                        testicular germ cell tumours [1521]. However, these data need confirmation in an ethnically and geographically
                        matched case-control study setting. For genetic counselling it is worth noting that partial AZFc deletions, gr/gr
                        and b2/b3, may predispose to complete AZFc deletion in the next generation [1551].

                        10.3.5.3.1.4   Autosomal defects with severe phenotypic abnormalities and infertility
                        Several inherited disorders are associated with severe or considerable generalised abnormalities and infertility
                        (e.g., Prader-Willi syndrome [1552], Bardet-Biedl syndrome [1553], Noonan’s syndrome, Myotonic dystrophy,
                        dominant polycystic kidney disease  [1554, 1555], and 5  α-reductase deficiency  [1556-1559], etc.). Pre-
                        implantation genetic screening may be necessary in order to improve the ART outcomes among men with
                        autosomal chromosomal defects [1560, 1561].

                        10.3.5.4   Sperm chromosomal abnormalities
                        Sperm can be examined for their chromosomal constitution using FISH both in men with normal karyotype and
                        with anomalies. Aneuploidy in sperm, particularly sex chromosome aneuploidy, is associated with severe damage
                        to spermatogenesis [1483, 1562-1564] and with translocations and may lead to recurrent pregnancy loss (RPL) or
                        recurrent implantation failure [1565]. In a large retrospective series, couples with normal sperm FISH had similar
                        outcomes from IVF and ICSI on pre-implantation genetic screening (PGS). However, couples with abnormal FISH
                        had better clinical outcomes after PGS, suggesting a potential contribution of sperm to aneuploidic abnormalities
                        in the embryo [1566]. In men with sperm aneuploidy, PGS combined with IVF and ICSI can increase chances of
                        live births [1482].

                        10.3.5.5   Measurement of Oxidative Stress
                        Oxidative stress is considered to be central in male infertility by affecting sperm quality, function, as well as the
                        integrity of sperm [1567]. Oxidative stress may lead to sperm DNA damage and poorer DNA integrity, which are
                        associated with poor embryo development, miscarriage and infertility [1568, 1569]. Spermatozoa are vulnerable
                        to oxidative stress and have limited capacity to repair damaged DNA. Oxidative stress is generally associated
                        with poor lifestyle (e.g., smoking) and environmental exposure, and therefore antioxidant regimens and
                        lifestyle interventions may reduce the risk of DNA fragmentation and improve sperm quality [1570]. However,
                        these  data  have  not  been  supported  by  RCTs. Furthermore,  there  are  no  standardised  testing  methods  for
                        ROS and the duration of antioxidant treatments. Although ROS can be measured by various assays (e.g.,
                        chemiluminescence), routine measurement of ROS testing should remain experimental until these tests are
                        validated in RCTs [1571].




                        SEXUAL AND REPRODUCTIVE HEALTH - MARCH 2021                                       135
   131   132   133   134   135   136   137   138   139   140   141